接受中等疗效和高疗效疾病修正治疗的多发性硬化女性宫颈异常风险
这项多中心队列研究纳入248例多发性硬化女性,数据来自1998至2019年澳大利亚维多利亚州三个登记系统的记录链接。暴露于中等高疗效疾病修正治疗者宫颈筛查异常发生率为每1000患者年36.6例,未暴露者为每1000患者年10.2例;暴露与宫颈异常风险升高相关(风险比3.79,95%CI 2.02-7.08)。
要点
- 暴露于中等高疗效疾病修正治疗的多发性硬化女性宫颈筛查异常发生率为每1000患者年36.6例。
- 未暴露者宫颈筛查异常发生率为每1000患者年10.2例,两组差异有统计学意义(p < 0.001)。
- 暴露于较高疗效治疗者发生宫颈异常的风险比为3.79(95%CI 2.02-7.08)。
核心结论
- 作者认为若未来研究证实,主张将暴露于中等高疗效疾病修正治疗的多发性硬化女性按免疫缺陷人群模式纳入宫颈筛查和HPV疫苗接种规划。
- 本研究提供III级证据表明高活性多发性硬化治疗较低活性治疗增加多发性硬化女性发生宫颈异常的风险。
研究设计与样本
- 多中心队列研究,数据收集于1998至2019年澳大利亚维多利亚州。
- 通过MSBase登记系统、国家人乳头瘤病毒(HPV)疫苗接种规划登记系统和维多利亚州宫颈细胞学登记系统的匹配记录进行数据链接。
- 共纳入248例多发性硬化女性。
- 主要结局为细胞学或组织学确定的任何类型宫颈异常。
- 采用生存分析方法评估宫颈筛查检测发现宫颈异常的时间,使用粗化和调整Cox比例风险模型确定疾病修正治疗与宫颈异常风险关联的时间及强度。
主要发现
- 未暴露于中等高疗效治疗女性宫颈筛查异常发生率为每1000患者年10.2例(95%CI 5.5-14.9),低于暴露者的每1000患者年36.6例(95%CI 21.7-51.6),差异有统计学意义(p < 0.001)。
- 暴露于较高疗效治疗者发生宫颈异常的风险比为3.79(95%CI 2.02-7.08,p < 0.001),相对于未暴露者。
- 调整HPV疫苗接种状态、吸烟、激素避孕使用和社会经济状态后,风险仍升高,风险比为3.79(95%CI 1.99-7.21,p < 0.001)。
- 边际风险比随时间下降,20岁时为3.90(95%CI 2.09-7.27),70岁时为2.06(95%CI 1.14-3.73)。
关键数值与推荐
- 暴露于中等高疗效治疗女性宫颈筛查异常发生率为每1000患者年36.6例(95%CI 21.7-51.6)。
- 未暴露女性宫颈筛查异常发生率为每1000患者年10.2例(95%CI 5.5-14.9)。
- 暴露于较高疗效治疗者宫颈异常风险比为3.79(95%CI 2.02-7.08,p < 0.001)。
- 调整后风险比为3.79(95%CI 1.99-7.21,p < 0.001)。
- 边际风险比20岁时为3.90(95%CI 2.09-7.27),70岁时为2.06(95%CI 1.14-3.73)。
临床怎么用
- 作者认为若未来研究证实,主张将暴露于中等高疗效疾病修正治疗的多发性硬化女性按免疫缺陷人群模式纳入宫颈筛查和HPV疫苗接种规划。
- 本研究提供III级证据表明高活性多发性硬化治疗较低活性治疗增加多发性硬化女性发生宫颈异常的风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: The impact of immunomodulatory therapies on the risk of cervical pre-cancer and invasive cancer development is important for the health and safety of women with multiple sclerosis (wwMS). We investigate the risk of cervical abnormalities in wwMS treated with disease-modifying therapies (DMTs). METHODS: This is a multicenter cohort study with data collected from 1998 to 2019 in Victoria, Australia. Data linkage was performed using matching records from the MSBase Registry, the National Human Papillomavirus (HPV) Vaccination Program Register, and the Victorian Cervical Cytology Register. The primary outcome was the detection of any type of cervical abnormality as determined by cytology or histology. Survival methods were used to assess the time to cervical abnormality detection on cervical screening tests (CSTs). Crude and adjusted Cox proportional hazards models were used to determine time to and magnitude of association of DMTs with the risk of cervical abnormality. In a sensitivity analysis, we constructed standardized survival curves averaged over the same set of covariates to determine the commensurate population-average (marginal) causal effects. RESULTS: We included 248 wwMS. The incidence of abnormal CSTs was lower (p < 0.001) for women not exposed to moderate-high-efficacy therapy (10.2 per 1,000 patient-years [95% confidence interval (CI) 5.5-14.9]), compared with those exposed (36.6 per 1,000 patient-years [95% CI 21.7-51.6]). Exposure to higher efficacy treatment was associated with a 3.79-fold increased hazard (95% CI 2.02-7.08, p < 0.001) of developing a cervical abnormality relative to those not exposed. When adjusted for vaccination status, smoking, hormonal contraceptive use, and socioeconomic status, the risk remained elevated at 3.79 (95% CI 1.99-7.21, p < 0.001). Marginal hazard ratios declined over time, ranging from 3.90 (95% CI 2.09-7.27) at 20 years of age to 2.06 (95% CI 1.14-3.73) at 70 years of age. DISCUSSION: A greater than three-and-a-half-fold increased risk of cervical abnormalities was found after exposure to moderate-high-efficacy DMTs. This risk persisted despite adjusting for HPV vaccination status, hormonal contraception use, smoking, and socioeconomic status. If confirmed in future studies, we would advocate for wwMS exposed to moderate-high-efficacy DMTs to be treated in line with immune-deficient paradigm in cervical screening and HPV vaccination programs. CLASSIFICATION OF EVIDENCE: This study provides Class III evidence that highly active MS therapy compared with less active therapy increases the risk of developing cervical abnormalities among women with MS.
引用
- Bridge F, Brotherton J, Stankovich J, et al. Risk of Cervical Abnormalities for Women With Multiple Sclerosis Treated With Moderate-Efficacy and High-Efficacy Disease-Modifying Therapies. Neurology. 2024. PMID: 38306594. doi:10.1212/WNL.0000000000208059
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。